Latest research on Sevelamer

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.

Sevelamer interactions

None of the phosphate binders, except Sevelamer, was associated to the value of serum Calcium. [source, 2016]
Patients on Sevelamer show serum Calcium levels slightly higher than patients not taking Sevelamer. [source, 2016]
This may reflect the fact that Sevelamer was given to patients with high Calcium to avoid Calcium containing Calcium binders. [source, 2016]
Serum P level was associated to the use of phosphate binders: Calcium binders, Sevelamer and lanthanum without significant differences among the phosphate binders [source, 2016]
His regular medications included Irbesartan 150 mg once a day, Amlodipine 5 mg once a day, Simvastatin 20 mg once a day, alfacalcidol 0.25 microgram once a day and Sevelamer 800 mg three times a day with meals. [source, 2016]
Moreover, sucroferric oxyhydroxide was able to reduce serum phosphate and intact Parathyroid hormone concentrations and prevent the development of vascular calcifications in a rat model of chronic renal failure as effectively as lanthanum carbonate and Sevelamer carbonate. [source, 2016]
She was also on Sevelamer, Hydroxyurea, Folic acid supplements, Amiodarone, and Ramipril, but was not taking Calcium salt and Vitamin D supplements. [source, 2016]
However, we do not believe that Sevelamer was incidentally adherent to the Mucosa as a result of an underlying colonic disease process, including IBD, CMV colitis or diverticulitis, since no such intestinal pathology was documented on the biopsies. [source, 2016]
The most frequently studied renal-specific medications were phosphate binders (76.1%, n = 35), with eight studies [27,32,48,49,52,54,58,61] specifically mentioning the types of phosphate binders prescribed (Aluminium hydroxide, Calcium Acetate'>Calcium Acetate, Calcium carbonate, lanthanum carbonate, and Sevelamer hydrochloride). [source, 2015]
For Capecitabine, peginterferon alpha-2a, and Sevelamer hydrochloride, the number of ADR reports reached its peak within 6 months after marketing. [source, 2015]